Health Care & Life Sciences » Biotechnology | UCB

UCB

UCB S.A. ADR
Stock Exchange Other OTC
EPS
 $2.5
Market Cap
 $15.84 B
Shares Outstanding
 389.01 M
Public Float
 -
UCB S.A.
Stock Exchange Euronext Brussels
EPS
 EUR4.2
Market Cap
 EUR14.06 B
Shares Outstanding
 194.51 M
Public Float
 119.7 M
UCB S.A.
Stock Exchange Frankfurt Stock Exchange
EPS
 -
Market Cap
 -
Shares Outstanding
 188.54 M
Public Float
 -
UCB S.A.
Stock Exchange London Stock Exchange
EPS
 EUR4.2
Market Cap
 EUR14.07 B
Shares Outstanding
 188.54 M
Public Float
 -

Profile

Address
Allée de la Recherche, 60
Brussels BU 1070
Belgium
Employees -
Website http://www.ucb.com
Updated 07/08/2019
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Financials

View All
Created with Highcharts 5.0.14UCB S.A.Net Income. Fiscal year is January-December. All values EUR Millions.828211511526426454354375275279279220132014201520162017201802004006008001000
Created with Highcharts 5.0.14UCB S.A.Sales/Revenue. Fiscal year is January-December. All values EUR Millions.3 1333 1333 3443 3443 8763 8764 1474 1474 5304 5304 6324 63220132014201520162017201801k2k3k4k5k

Evelyn du Monceau
Chairman
Jean-Christophe Tellier
Chief Executive Officer & Executive Director
View All

StatInvestor

Privacy Policy
Feedback

© 2025 StatInvestor All Rights Reserved.